United Therapeutics reaches patent settlement with Actavis

Silver Spring biotech United Therapeutics Corp.'s share price was largely unchanged Friday after announcing it settled litigation with Actavis Laboratories FL Inc. in a deal that will allow that company to market a generic version of one of United Therapeutics' hypertension drugs. Under the settlement, United Therapeutics (NASDAQ: UTHR) grants the Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) subsidiary a license to manufacture and commercialize a generic version of Orenitram — an extended-release,…
Source: bizjournals.com Health Care:Biotechnology headlines - Category: Biotechnology Authors: Source Type: news